|Bid||26.15 x 900|
|Ask||26.21 x 1300|
|Day's Range||26.10 - 28.19|
|52 Week Range||10.54 - 32.54|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
SALT LAKE CITY, May 05, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference at 2:45 p.m. EDT on May 12, 2021. The presentation will be available via a live audio webcast accessible at the following direct link (link) or through the investor information section of Myriad’s website at www.myriad.com. About Myriad Genetics Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to improving and transforming patient lives worldwide. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information, please visit the company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Media Contact: Jared Maxwell Investor Contact:Scott Gleason (801) 505-5027 (801) 584-1143 email@example.com firstname.lastname@example.org
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Revenues for the genetic testing company were higher than expected, and the per-share loss was smaller.